Retiver

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Retiver

Quick Facts

Property Description
Active Ingredient Calcium Dobesilate (INN)
Pharmacological Class Vasoprotective Agent (Capillary-Protective)
Dosage Form(s) Capsule (Oral), Rectal Cream (Topical)
Origin/Type Synthetic Molecule
General Purpose Stabilizes microcirculation and reduces vascular leakage

Retiver: Definition and Pharmacological Classification

Retiver is a brand name for a medicinal product whose principal active ingredient is the synthetic molecule Calcium Dobesilate. It is classified as a vasoprotective agent, belonging to the therapeutic class designed to stabilize and enhance the structural integrity of blood vessels. This categorization is confirmed by its official classification under the World Health Organization (WHO) ATC code C05BX01, which places it among antivaricose and other sclerosing agents. Pharmacological studies have supported its efficacy in reducing microvascular permeability, differentiating its action from systemic blood pressure treatments.

Compositional Forms and General Therapeutic Purpose

Retiver is available in distinct dosage form(s): the oral Capsule (for systemic action) and the Rectal Cream (for localized treatment). The oral form typically delivers the single active ingredient, Calcium Dobesilate. The Rectal Cream, however, is commonly supplied as a fixed-dose combination product. This formulation uniquely integrates the vasoprotective agent with components such as a local anesthetic (Lidocaine) and a corticosteroid (Hydrocortisone), alongside zinc, to provide both structural capillary support and immediate symptomatic relief during its topical route of administration. This dual-action approach is clinically recognized for addressing vascular health while managing localized discomfort.

How Does Retiver Support Vascular Function? (High-Level Principle)

The fundamental action of Calcium Dobesilate is to stabilize the microvascular system. It achieves this by decreasing excessive capillary permeability and enhancing the mechanical resistance of the microvascular wall. This core mechanism helps prevent the abnormal leakage of fluid and blood components from the small vessels into the surrounding tissues. By supporting the integrity of the microcirculation, the medicine’s general purpose is to mitigate vascular imbalance, which ultimately helps to relieve generalized discomfort, localized tissue swelling (edema), and the associated feelings of limb heaviness.

Regulatory References

  1. Summary of Product Characteristics (SmPC)

What side effects are possible with Retiver?

Possible Side Effects and Safety Information: Retiver

Retiver, which contains the active ingredient Calcium Dobesilate, is generally well-tolerated. However, like all medications, it may cause side effects in some individuals. Most adverse reactions are temporary and typically resolve as the body adjusts to the treatment.

Common Side Effects

The most frequently reported side effects associated with oral Retiver include gastrointestinal disturbances and skin reactions. These can manifest as:

  • Nausea and/or vomiting
  • Diarrhea
  • Stomach discomfort
  • Skin rash
  • Fever
  • Joint pain (arthralgia)

Serious but Rare Side Effects

A rare, but serious potential side effect is agranulocytosis (a severe reduction in white blood cells). Patients should immediately contact their healthcare provider if they develop any signs of infection, such as high fever, sore throat, or symptoms of inflammation, as these could indicate a blood cell disorder requiring urgent attention.

Contraindications and Precautions

  • Hypersensitivity: Retiver is contraindicated in patients with a known allergy or hypersensitivity to Calcium Dobesilate or any of the product's components.
  • Pregnancy and Breastfeeding: Use during pregnancy and breastfeeding should only be undertaken after consulting a doctor, who will assess the potential benefits against the risks. Limited human data is available.
  • Organ Function: Caution and potential dose adjustment may be necessary for patients with moderate to severe kidney impairment or severe liver disease. Consult your physician for guidance if you have pre-existing conditions.
Precaution Guidance
Alcohol Avoid or limit consumption due to potential for increased drowsiness.
Drowsiness Use caution when driving or operating heavy machinery if you experience drowsiness or vision disturbances.

It is essential to inform your doctor about all medications, supplements, and herbal products you are currently taking to prevent potential drug interactions.

Overdose and Emergency Response

The official regulatory profile for Retiver (Calcium Dobesilate) emphasizes actions required for managing severe toxicity, as no cases of acute overdose have been formally reported to date in official prescribing information. Specific acute overdose manifestations are therefore not detailed in regulatory documents.

When Immediate Medical Help is Required

Urgent medical attention is required when specific serious symptoms occur. Patients must seek immediate medical help and discontinue treatment if they develop signs of infection, such as high fever, sore throat, oral inflammation, or sudden skin reactions. This regulatory guidance addresses the risk of Agranulocytosis, a rare but severe blood disorder that requires mandatory, urgent control of the blood formula and leucogram. This severe adverse outcome has been reported mainly in elderly patients.

Official Management Measures

In the context of a suspected overdose, regulatory documents specify that the treatment approach is supportive and symptomatic. Procedures such as induced emesis (vomiting) and gastric lavage are documented as potential management measures. There is no specific antidote listed in the official labeling.

Therapeutic Uses of Retiver

What Retiver Treats: Main Uses and Benefits

Supportive Management of Chronic Venous Symptoms

Retiver is commonly used across conditions presenting with systemic microcirculatory issues, particularly Chronic Venous Insufficiency (CVI) and its symptomatic manifestations, such as varicose veins. The medication is used in the therapeutic area of vasoprotection. It helps address symptom clusters that create noticeable physiological strain, including persistent leg heaviness, uncomfortable night cramps, and significant ankle swelling (edema).

Relief for Localized Acute Vascular Flare-ups

This medication is applied in contexts where additional symptomatic management is appropriate, most notably for hemorrhoidal disease (piles). It is relevant in clinical settings marked by increased discomfort or tension, helping to address pronounced symptoms that become more disruptive during flare-ups, such as localized pain, inflammation, itching, and bleeding. Retiver provides support that generally helps ease the overall symptom burden, helping improve day-to-day comfort during symptomatic periods.

Stabilization Support for Microvascular Complications

Retiver is used across therapeutic domains involving chronic conditions that affect small blood vessels, particularly for patients with diabetes who exhibit complications like Diabetic Retinopathy. It is relevant in situations where additional management of discomfort and progression is required. The practical benefit is its supportive role in mitigating progressive microvascular damage, which may be part of symptomatic management.


Quick Fact: Relief for Venous Heaviness and Pain This medication is often used during phases when symptoms of venous congestion, such as leg pain and swelling, become more noticeable, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Retiver (Calcium Dobesilate) eligibility is strictly defined by regulatory documents, distinguishing between permitted use, absolute prohibitions, and conditional restrictions.

Eligibility scope

Category Official Regulatory Statement
Populations for whom use is allowed Primarily Adults (18 years and over). Use in the older adult population is generally the same as in adults.
Populations for whom use is contraindicated Patients with known hypersensitivity or allergy to Calcium Dobesilate or any of the formulation's excipients.
Age-related eligibility rules Not recommended for use in children and adolescents (under 18 years) due to insufficient data for routine use.
Condition-specific eligibility rules Severe Renal Insufficiency requiring dialysis mandates a reduction of the dosage. Use requires special caution in patients with a history of peptic ulcer or recurrent gastritis.
Pregnancy and lactation eligibility status Pregnancy: Use is highly conditional and should only be administered if the potential benefit justifies the potential risk to the fetus. Lactation: Either the treatment or breastfeeding should be stopped as a precaution.
Eligibility-related restrictions Treatment must be immediately stopped if a patient develops signs of infection (e.g., high fever, sore throat), as this may indicate a severe blood disorder.

Eligibility classifications (high-level)

The medicine is subject to absolute ban (allergy) and conditional use for populations based on Age, Organ Function, and Reproductive Status, all as formally defined in official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Co-administered Medicines

The interaction profile for Retiver (Calcium Dobesilate) is primarily defined by a substantial absence of officially documented drug-drug interactions in regulatory prescribing information. According to official sources, no specific medicines or product categories are formally listed as interacting based on pharmacokinetic or pharmacodynamic mechanisms.

Regulatory labels confirm that no specific medicinal products are formally contraindicated for co-administration due to an interaction risk. Similarly, no mandatory timing separation requirements are specified for taking Retiver alongside other pharmaceuticals, nor are there formally documented interactions with food, alcohol, or common herbal supplements.

Procedural and Laboratory Interference

The main constraint officially noted in the prescribing information relates to diagnostic accuracy, not drug co-administration. Retiver is documented to interfere with certain enzymatic laboratory assays used to quantify serum creatinine. This interference occurs because the active substance can alter the chemical process in assays that rely on the Trinder reaction.

This interaction is classified as a procedural constraint because it results in the analytical measurement of creatinine potentially yielding artificially lower values. This potential for interference is also noted to extend to the laboratory determination of other analytes that use the same Trinder reaction process, such as uric acid, total cholesterol, and triglycerides.

Mechanism of Action

Endothelial Barrier Modulation

This core mechanism involves molecular action on the capillary wall, influencing the structural dynamics of the endothelial barrier and reinforcing tight junction proteins (such as ZO-1). This physical action restricts the passage of fluid and plasma components from the vessels, which results in a physiological outcome of restricted fluid passage across the endothelial barrier.


Antioxidant and Anti-inflammatory Pathway Modulation

The mechanism involves biochemical modulation by acting as an antioxidant scavenger against Reactive Oxygen Species ( ROS) and functioning as an inhibitor of factors like VEGF and the NF-kappa B inflammatory pathway. These actions result in the downregulation of localized vascular inflammation and a modulation of microvascular resistance.


Localized Signal Modulation (Combination Products)

In fixed-dose combinations, the mechanism is supplemented by the action of Lidocaine ( Sodium Channel Blocker) and Hydrocortisone ( GR Agonist). This mechanism of action leads to functional modulation by inhibiting nerve impulse conduction and modulating the acute inflammatory cascade at the local tissue level.

Dosage and Administration Information

How to Use Retiver: Official Administration Guidelines

Retiver is the brand name for a medicine containing Calcium Dobesilate, which is typically administered through two main methods: the oral capsule for systemic use and a topical/rectal cream (often a combination product) for localized use.

Official Dosing and Frequency

The standard oral dosage for adults is typically a total daily intake ranging from 500 mg to 1000 mg of the active ingredient. This regimen is generally structured to be taken once or twice daily, with the specific amount determined by the condition being managed. The capsule is swallowed whole with water and is generally taken with the main meals.

For the topical/rectal form, application is scheduled 2 to 3 times daily in the affected area, preferably in the morning and at bedtime, and, if possible, following defecation. The duration of use for the cream is typically short-term, often a few days or up to 1 to 2 weeks, while the systemic oral treatment may continue for several weeks to months, based on clinical protocols.

Population-Specific Use

It is standard practice that a dose reduction is necessary for adult patients who have severe renal insufficiency requiring dialysis. For older adults, the dosing recommendations generally align with those for other adults. However, a routine pediatric dosage is not established, as there is insufficient data to recommend its use in children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Retiver (Calcium Dobesilate)

This section provides an overview of the types of research and clinical trials that have evaluated the use of Retiver, detailing the scope of the evidence and what the studies have observed so far, according to official and peer-reviewed sources. Study results reflect the specific conditions under which they were conducted.

Evidence for Use in Chronic Venous Symptoms

The research base for Retiver's use in conditions characterized by symptoms like leg heaviness and ankle swelling is supported by systematic reviews and meta-analyses. These authoritative reviews look across multiple Randomized Controlled Trials (RCTs), which typically compared the medicine to a placebo over a defined time interval.

Studies explored outcomes related to physical discomfort and physiological strain, measuring changes in patient-reported symptoms and objective physiological measures, including changes in ankle and calf circumference to assess the pattern of fluid accumulation or edema. Studies reported changes in measured outcomes related to physical discomfort relative to the control groups. Research highlights patterns in ankle and calf volume measurements in the populations observed. However, the follow-up durations were often limited to short-term assessment periods, typically less than three months.

Evidence for Use in Microvascular Complications (Diabetic Retinopathy)

Retiver was studied for its use in chronic conditions that affect small blood vessels, such as non-proliferative diabetic retinopathy. The evidence for this therapeutic area is derived from long-term, controlled clinical trials that observed responses over defined time intervals, sometimes lasting several years.

Research examined outcomes related to how studies measured the rate of progression, often using a specialized clinical scale. Studies monitored physiological strain by assessing the integrity of the blood-retinal barrier. Studies described patterns in the progression of the condition in some observed groups over a period of 12 months or longer.

What is Still Uncertain about the Research

Transparency requires acknowledging that certain aspects of the evidence landscape are still emerging. Evidence quality varies across studies, particularly with older trials that have been noted for methodological limitations. The scientific literature reports that for Diabetic Retinopathy, findings were mixed between different studies, and the clinical significance of some observations remains a subject of ongoing discussion. Furthermore, comparative evidence is lacking, as most research focused on comparing the medicine against a placebo or supportive measures rather than against all other venoactive treatments.

Key Studies & References

  1. Role of calcium dobesilate in management of internal haemorrhoid: An interventional study
  2. Assessment of the Tolerance of Dobenox Forte® in Patients with Chronic Venous Disease

Frequently Asked Questions (FAQ)

Common questions about Retiver (FAQ)


Q: How long after stopping Retiver does it stay in your system?

Information from pharmacokinetic studies shows that the elimination half-life of Calcium Dobesilate is approximately 5 hours. This figure describes the time it takes for half of the medicine to be removed from the bloodstream. The medicine’s clearance is primarily described as occurring through the kidneys and faeces.


Q: What happens if I miss a scheduled dose of Retiver?

Official patient information states that if a dose of the medicine is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official instructions indicate that a double dose is not to be taken to compensate for a missed dose.


Q: What kind of studies have been done on Retiver?

The evidence base for this medicine includes different types of research, such as Randomized Controlled Trials (RCTs) and systematic reviews. These studies typically compare the medicine against a placebo or supportive measures, and have examined its efficacy and safety profile for the approved conditions.


Q: Can Retiver interact with herbal supplements like St. John's Wort?

According to official prescribing information, there is a substantial absence of formally documented drug-drug and drug-supplement interactions for Retiver. No specific interaction with St. John's Wort or other common herbal supplements is listed in regulatory documents.


Q: What is the general long-term safety profile of Retiver?

Official information states that rare but serious side effects, such as blood disorders like agranulocytosis or liver dysfunction, may require monitoring if the medicine is used for a prolonged period. Official guidance suggests that monitoring may be considered for patients using the medicine over an extended period.


Q: Is Retiver the same kind of medicine as [similar common drug name]?

Retiver's active ingredient, Calcium Dobesilate, is officially classified as a vasoprotective agent. This is a category for drugs designed to stabilize and protect blood vessel walls. This classification describes its primary mechanism, which is separate from that of other classes of medicines that may be used for similar conditions.


Q: Can Retiver be taken long-term?

Treatment protocols outlined in official documents can describe use for a duration ranging from several weeks to months, depending on the condition being managed. Official documents indicate that long-term use may require monitoring for rare side effects, as noted in the official precautions.


Q: Does Retiver have a generic version available?

Retiver contains the active ingredient Calcium Dobesilate, which is the International Nonproprietary Name (INN) for the drug substance. Because Calcium Dobesilate is the generic name, it is marketed globally by various manufacturers under many different brand names.


Q: Are there any major diet restrictions when using Retiver?

Official documents confirm that there are no formally documented food or major diet restrictions specified for use with Retiver. The oral capsule is typically directed to be taken with the main meals, but no specific food or ingredient needs to be avoided.


Q: Is a headache a common side effect of Retiver?

Headache is listed as a reported side effect of Retiver in official documents. However, based on the frequency data in regulatory safety summaries, it is generally considered a less common side effect compared to the most frequently reported gastrointestinal issues and skin reactions.


Q: Is Retiver used for any conditions other than the main one listed?

Official documents list the medicine's use for Chronic Venous Symptoms (like leg heaviness) and Diabetic Retinopathy (a complication of diabetes). In some regulatory jurisdictions, it is also indicated for other microcirculatory disorders associated with chronic venous insufficiency.


Q: Is it normal to feel a bit drowsy when starting Retiver?

The potential for drowsiness or disturbances in vision is noted in the official precautions for Retiver. If these effects occur, official precautions state that caution should be exercised when driving or operating heavy machinery.


Q: Do you need a special prescription for Retiver?

Retiver is classified as a medicine that requires a prescription in most countries, as indicated by the reference to official documents like the Summary of Product Characteristics (SmPC) and Prescribing Information.


Q: What should I know about taking Retiver if I also have diabetes?

The medicine is specifically studied and approved for treating the microvascular complications of diabetes, such as diabetic retinopathy. Official documents do not list general diabetes-specific precautions beyond the condition being treated itself.


Q: Is there any research on Retiver for use in children?

The use of Retiver is not recommended in children and adolescents (under 18 years), based on official statements. The reason for this is stated as insufficient data to establish a routine dosage and standard use guidelines for this population.


Q: Is Retiver available in different strengths?

Retiver is officially available as a 500 mg oral capsule. While other forms, such as a rectal cream combination with other active ingredients, are also approved, the standard oral form is typically the 500 mg strength.


Q: Is Retiver approved in countries outside of the United States?

Yes, Retiver (Calcium Dobesilate) is approved and marketed in many countries globally across Europe, Asia, Africa, and other regions. This is evidenced by the regulatory documents referenced from multiple international health authorities.


Q: Why are there different versions of Retiver mentioned online?

Different versions may be mentioned online due to two primary factors. First, the active ingredient is sold under various brand names globally. Second, the medicine is approved in different approved dosage forms, such as the oral capsule and the topical/rectal cream combination product.


Q: Are there any blood tests required before or during Retiver treatment?

Regulatory warnings advise that if a patient develops signs of infection, such as high fever or sore throat, official regulatory warnings suggest that a blood count test should be considered immediately. This is a precaution to check for the rare, severe blood disorder called agranulocytosis.


Q: Is Retiver habit-forming or addictive?

Retiver is a non-controlled substance. According to regulatory classifications in international jurisdictions, the medicine is not classified as a habit-forming or addictive substance.


Q: Can Retiver be crushed or chewed?

The official instructions for the Retiver capsule state clearly that it must be swallowed whole with water. It is not directed to be crushed, chewed, or opened before being taken.


Q: If I have a history of heart issues, can I still take Retiver?

Official regulatory information does not list a general history of heart issues as one of the formal contraindications for Retiver. Warnings and precautions are primarily focused on patients with known severe renal or liver impairment, and hypersensitivity.


Q: Can Retiver cause liver issues?

Official safety information notes that in rare cases, Retiver may be associated with signs of liver dysfunction. Caution and potential dose adjustment are also noted for patients who already have pre-existing severe liver disease.


Q: Is it possible to be allergic to Retiver?

Yes, official documents state that Retiver is contraindicated (should not be used) in patients with a known history of allergy or hypersensitivity to the active ingredient or any of the product's components, which defines that the medicine must not be used.

How should Retiver be stored and disposed of?

The storage and disposal of Retiver (Calcium Dobesilate) must comply with official regulatory labeling to ensure product stability.

Official Storage Conditions

  • Temperature: Store at controlled room temperature, which is at or below 30 C (86 F), and the product must not be frozen.
  • Protection: The medicine must be protected from light and excessive humidity.
  • Container: Keep Retiver in its original container and the container must be kept tightly closed. Oral capsules must remain in the blister packaging until use.
  • Child Safety: The medication must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Retiver should be disposed of through a drug take-back program or an authorized pharmaceutical waste collection point. The product must not be discarded via wastewater or common household trash unless a specific method is authorized by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Retiver found in:

A-Z Index: